BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 11477444)

  • 21. Pharmacokinetics of liposomal busulphan in man.
    Hassan Z; Ljungman P; Ringdén O; Winiarski J; Nilsson C; Aschan J; Whitley HR; Hassan M
    Bone Marrow Transplant; 2001 Mar; 27(5):479-85. PubMed ID: 11313681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation.
    Ward J; Kletzel M; Duerst R; Fuleihan R; Chaudhury S; Schneiderman J; Tse WT
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1612-21. PubMed ID: 26025482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia.
    Pawlowska AB; Blazar BR; Angelucci E; Baronciani D; Shu XO; Bostrom B
    Bone Marrow Transplant; 1997 Dec; 20(11):915-20. PubMed ID: 9422469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
    Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
    Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation.
    Saito T; Kanda Y; Nakai K; Kim SW; Arima F; Kami M; Tanosaki R; Tobinai K; Wakasugi H; Heike Y; Mineishi S; Takaue Y
    Bone Marrow Transplant; 2003 Sep; 32(6):601-8. PubMed ID: 12953133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients.
    Westerhof GR; Ploemacher RE; Boudewijn A; Blokland I; Dillingh JH; McGown AT; Hadfield JA; Dawson MJ; Down JD
    Cancer Res; 2000 Oct; 60(19):5470-8. PubMed ID: 11034090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of two conditioning regimens in treatment of leukemia by allogeneic hematopoietic stem cell transplantation].
    Zhang GC; Zheng D; Guan XX; Luo SK; Li J; Peng AH; Tong XZ; Lai FZ; Tan EX; Hong WD
    Ai Zheng; 2003 Jun; 22(6):620-3. PubMed ID: 12948413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.
    Gaziev J; Isgrò A; Mozzi AF; Petain A; Nguyen L; Ialongo C; Dinallo V; Sodani P; Marziali M; Andreani M; Testi M; Paciaroni K; Gallucci C; De Angelis G; Alfieri C; Ribersani M; Lucarelli G
    Pediatr Blood Cancer; 2015 Apr; 62(4):680-6. PubMed ID: 25557687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic bone marrow stem cell transplantation following CD34+ immunomagnetic enrichment in patients with inherited metabolic storage diseases.
    Gaipa G; Dassi M; Perseghin P; Venturi N; Corti P; Bonanomi S; Balduzzi A; Longoni D; Uderzo C; Biondi A; Masera G; Parini R; Bertagnolio B; Uziel G; Peters C; Rovelli A
    Bone Marrow Transplant; 2003 May; 31(10):857-60. PubMed ID: 12748661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia.
    Doney KC; Chauncey T; Appelbaum FR;
    Bone Marrow Transplant; 2002 May; 29(10):817-23. PubMed ID: 12058231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma.
    Vassal G; Tranchand B; Valteau-Couanet D; Mahé C; Couanet D; Schoeppfer C; Grill J; Kalifa C; Hill C; Ardiet C; Hartmann O
    Bone Marrow Transplant; 2001 Mar; 27(5):471-7. PubMed ID: 11313680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
    Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Busulphan level and early mortality in thalassaemia patients after BMT.
    Li CK; Yuen PM; Wong R; Pang CP; Lai WK; Law E; Shing MM; Chik KW; Leung TF
    Bone Marrow Transplant; 1999 Feb; 23(4):307-10. PubMed ID: 10100572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
    Demirer T; Buckner CD; Appelbaum FR; Bensinger WI; Sanders J; Lambert K; Clift R; Fefer A; Storb R; Slattery JT
    Bone Marrow Transplant; 1996 Apr; 17(4):491-5. PubMed ID: 8722344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
    Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
    Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.
    Mattsson J; Uzunel M; Remberger M; Hassan M
    Bone Marrow Transplant; 2003 Sep; 32(5):477-83. PubMed ID: 12942093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
    Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
    Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.
    Andersson BS; Madden T; Tran HT; Hu WW; Blume KG; Chow DS; Champlin RE; Vaughan WP
    Biol Blood Marrow Transplant; 2000; 6(5A):548-54. PubMed ID: 11071260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of an Oral Busulfan Test Dose in Patients Undergoing Hematopoietic Stem Cell Transplantation Treated With or Without Fludarabine.
    de Castro FA; Simões BP; Godoy AL; Bertagnoli Trigo FM; Coelho EB; Lanchote VL
    J Clin Pharmacol; 2016 Dec; 56(12):1555-1562. PubMed ID: 27130252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.